Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Cañete Hidalgo, Nuria
  • Bañares, Rafael
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p <0.001) and mortality (47% vs. 10%; p <0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality in patients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt., CIBERehd is funded by Instituto de Salud Carlos III . Juan Carlos Garcia - Pagan is supported by Ministerio de Educacion y Ciencia ( SAF - 2016 - 75767 - R ). Virginia Hernández - Gea is supported by Instituto de Salud Carlos III ( PI14/00182 ). Gilberto Silva - Junior is funded by CAPES Foundation, Ministry of Education of Brazil , Brasilia, Brazil (process number BEX 5960/13 - 4 ). Edilmar Alvarado is supported by a Rio Hortega Fellowship grant form Instituto de Salud Carlos III . Jonel Trebicka is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), European Union's Horizon 2020 Research and Innovation Programme ( Galaxy , No. 668031 and MICROB-PREDICT , No. 825694 ) and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875 ), and Cellex Foundation (PREDICT). Gu W is supported by the China Scholarships Council (CSC: #201906230332 ). Rafael Bañares is funded by Instituto de Salud Carlos III ( PI18/01901 ). Michael Praktiknjo is funded by the Ernst und Berta Grimmke Stiftung (Lfd.Nr. 5/19). The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis

  • Queck, Alexander
  • Thomas, Dominique
  • Jansen, Christian
  • Schreiber, Yannick
  • Rüschenbaum, Sabrina
  • Praktiknjo, Michael
  • Schwarzkopf, Katharina Maria
  • Mücke, Marcus Maximilian
  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Meyer, Carsten
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Geisslinger, Gerd
  • Trebicka, Jonel
  • Lange, Christian Markus
BACKGROUND: Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated. METHODS: Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein. RESULTS: While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001). CONCLUSIONS: Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03584204.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

2D shear wave liver elastography by aixplorer to detect portal hypertension in cirrhosis: an individual patient data meta-analysis

  • Thiele, Maja
  • Hugger, Mie B.
  • Kim, Yongsoo
  • Rautou, Pierre-Emmanuel
  • Elkrief, Laure
  • Jansen, Christian
  • Verlinden, Wim
  • Allegretti, Giulia
  • Israelsen, Mads
  • Stefanescu, Horia
  • Piscaglia, Fabio
  • García Pagán, Juan Carlos
  • Franque, Sven
  • Berzigotti, Annalisa
  • Castera, Laurent
  • Jeong, Woo K.
  • Trebicka, Jonel
  • Krag, Aleksander
Background & Aims: Liver stiffness measured with 2-dimensional shear wave elas- tography by Supersonic Imagine (2DSWE-SSI) is well-established for fibrosis diagnos- tics, but non-conclusive for portal hypertension. Methods: We performed an individual patient data meta-analysis of 2DSWE-SSI to identify clinically significant portal hypertension (CSPH), severe portal hyperten- sion and large varices in cirrhosis patients, using hepatic venous pressure gradient and upper endoscopy as reference. We used meta-analytical integration of diagnos- tic accuracies with optimized rule-out (sensitivity-90%) and rule-in (specificity-90%) cut-offs. Results: Five studies from seven centres shared data on 519 patients. After exclu- sion, we included 328 patients. Eighty-nine (27%) were compensated and 286 (87%) had CSPH. 2DSWE-SSI < 14 kPa ruled out CSPH with a summary AUROC (sROC), sensitivity and specificity of 0.88, 91% and 37%, and correctly classified 85% of pa- tients, with minimal between-study heterogeneity. The false negative rate was 60%, of which decompensated patients accounted for 78%. 2DSWE-SSI ≥ 32 kPa ruled in CSPH with sROC, sensitivity, specificity and correct classifications of 0.83, 47%, 89% and 55%. In a subgroup analysis, the 14 kPa cut-off showed consistent sensitivity and higher specificity for patients with compensated cirrhosis, without ascites, viral 2 aetiology or BMI < 25 kg/m . 2DSWE-SSI ruled out severe portal hypertension and large varices with fewer correctly classified and lower sROC, and with minimal benefit for ruling in. Conclusion: Liver stiffness using 2-dimensional shear wave elastography below 14 kPa may be used to rule out clinically significant portal hypertension in cirrhosis patients, but this would need validation in populations of compensated liver disease. 2DSWE-SSI cannot predict varices needing treatment.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The role of macrophage-inducible C-type lectin in different stages of chronic liver disease

  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Ortiz, Cristina
  • Torres, Sandra
  • Brol, Max J.
  • Tyc, Olaf
  • Gu, Wenyi
  • Grimm, Christian
  • Zeuzem, Stefan
  • Plamper, Andreas
  • Pfeifer, Philipp
  • Zimmer, Sebastian
  • Welsch, Christoph
  • Schaefer, Liliana
  • Rheinwalt, Karl P.
  • Clària i Enrich, Joan
  • Arroyo, Vicente
  • Trebicka, Jonel
  • Klein, Sabine
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Gu, Wenyi
  • Ibáñez Samaniego, Luis
  • Castellote Alonso, José
  • Silva Junior, Gilberto
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & Aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of trans-jugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p<0.001) and mortality (47% vs. 10%; p<0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality inpatients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?

  • Schwarzkopf, Katharina Maria
  • Eberle, Larissa
  • Uschner, Frank Erhard
  • Klein, Sabine
  • Schierwagen, Robert
  • Muecke, Marcus M.
  • Schaefer, Liliana
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Hintermann, Edith
  • Christen, Urs
  • Lange, Christian Markus
  • Trebicka, Jonel
  • Welsch, Christoph
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Statins: Old drugs as new therapy for liver diseases?

  • Pose Méndez, Elisa
  • Trebicka, Jonel
  • Mookerjee, Rajeshwar P.
  • Angeli, Paolo
  • Ginès i Gibert, Pere
In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large populations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins, with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial effects persisted after adjustment for disease severity and other potential confounders. Finally, a few randomised controlled trials have shown that treatment with simvastatin decreases portal pressure (two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects, further randomised controlled trials in large series of patients with hard clinical endpoints should be performed before statins can be recommended for use in clinical practice.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

  • Torres, Sandra
  • Ortiz, Cristina
  • Bachtler, Nadine
  • Gu, Wenyi
  • Grünewald, Leon D.
  • Kraus, Nico
  • Schierwagen, Robert
  • Hieber, Christoph
  • Meier, Caroline
  • Tyc, Olaf
  • Brol, Maximilian Joseph
  • Uschner, Frank Erhard
  • Nijmeijer, Bart
  • Welsch, Christoph
  • Berres, Marie-Luise
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trautwein, Christian
  • Vogl, Thomas J.
  • Zeuzem, Stefan
  • Trebicka, Jonel
  • Klein, Sabine
anus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo., Jonel Trebicka is supported by the German Research Foundation project ID 403224013–SFB 1382 (A09); by the German Federal Ministry of Education and Research (BMBF) for the DEEP‐HCC project; by the Hessian Ministry of Higher Education, Research, and the Arts (HMWK) for the ENABLE cluster project; and by Eurostars (Grant ID 12350). The MICROB‐PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects have received funding from the European Union's Horizon 2020 research and innovation program. The manuscript reflects only the authors' views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Palmitoylcarnitine impairs immunity in decompensated cirrhosis

  • Wei Zhang, Ingrid
  • Sánchez-Rodríguez, María Belén
  • López-Vicario, Cristina
  • Casulleras, Mireia
  • Duran-Güell, Marta
  • Flores-Costa, Roger
  • Aguilar, Ferran
  • Rothe, Michael
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trebicka, Jonel
  • Arroyo, Vicente
  • Clària, Joan
In patients with cirrhosis, acute decompensation (AD) correlates with a hyperinflammatory state driven by mitochondrial dysfunction, which is a significant factor in the progression toward acute-on-chronic liver failure (ACLF). Elevated circulating levels of acylcarnitine, indicative of mitochondrial dysfunction, are predictors of mortality in ACLF patients. Our hypothesis posits that acylcarnitines not only act as biomarkers, but also actively exert detrimental effects on circulating immune cells., Supported by the Plan Nacional de I+D funded by the Agencia Estatal de Investigación (grants PID2019-105240RB-I00 and PID2022-138970OB-I00 [to JC] and PID2019-111669RB-100 and PID2020-115055RB-I00 [to JCF-C]). JC laboratory is a Consolidated Research Group recognised by the Generalitat de Catalunya (2021 SGR 01323) and receives funds from EF CLIF and European Union’s Horizon 2020 research and innovation programme (MICROB-PREDICT [project ID 825694], DECISION [project ID 847949]). JCF-C receives funds from the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH, the Project 201916/31 by Fundació Marató TV3 and the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. JT is supported by the German Research Foundation project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research, the Arts for the ENABLE and ACLF-I cluster projects and the European Union’s Horizon 2020 research and innovation program for MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects. IWZ was supported by the Sheila Sherlock Post Graduate Programme of the European Association for the Study of the Liver., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

  • Torres, Sandra
  • Brol, Maximilian J.
  • Magdaleno, Fernando
  • Schierwagen, Robert
  • Uschner, Frank E.
  • Klein, Sabine
  • Ortiz, Cristina
  • Tyc, Olaf
  • Bachtler, Nadine
  • Stunden, James
  • Bertheloot, Damien
  • Kitanovic, Ana
  • Sanchez, Brian
  • Schrum, Jacob
  • Roush, William R.
  • Franchi, Luigi
  • Byth, Kate
  • Latz, Eicke
  • Trebicka, Jonel
Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel and selective NLRP3 antagonist in a murine dietary model of NASH. Methods: Groups of 12-week-old ApoE -/- mice were fed ad lib for 7 weeks with a methionine/choline deficient (MCD) and western diet (WD). After 3 weeks of diet-induced injury, mice were injected i. p. with the NLRP3 antagonist IFM-514 (100 mg/kg body weight) or vehicle (0.5% carmellose) every day, 5 days/week for a further 4 weeks. Several markers of inflammation, fibrosis and steatosis were evaluated. Whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed. Results: IFM-514 inhibited IL-1β production in mice challenged with 20 mg/kg lipopolysaccharide, and in mouse and human inflammatory cells in vitro. IFM-514 inhibited hepatic inflammation in the in vivo non-alcoholic steatohepatitis model assessed by H&E staining and in the hepatic gene expression of inflammasome-related proinflammatory cytokines. This effect was associated with significant reduction in caspase-1 activation. Similarly, IFM-514 was efficacious in vivo in MDC-fed ApoE -/- mice, markedly reducing portal pressure, Sirius red staining and 4-hydroxyproline content compared to vehicle-treated mice. Moreover, IFM-514 significantly reduced hepatic steatosis in MCD-fed ApoE -/- mice, as evidenced by NAFLD scores, oil red O staining, hepatic triglycerides and gene expression. In WD treated animals, similar trends in inflammation and fibrosis were observed, although not sufficient IFM-514 levels were reached. Conclusion: Overall, IFM-514 reduced liver inflammation and fibrosis, with mild effects on liver steatosis in experimental murine NASH. Blocking of NLRP3 may be an attractive therapeutic approach for NASH patients., This study received funding from the Deutsche Forschungsgemeinschaft (SFB TRR57 and CRC1382), European Union's Horizon 2020 Research and Innovation Programme (Galaxy, No. 668031, MICROB-PREDICT, No. 825694, and DECISION No. 84794), Societal Challenges-Health, Demographic Change, and Well-Being (No. 731875), Cellex Foundation (PREDICT), LIVERHOPE (No. 731875), Enable (funded by Hessian Ministry of Higher Education, Research, Science and the Arts) and deep-HCC (German Federal Ministry of Education and Research). These funders had no involvement in the design of the study., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

2D shear wave liver elastography by aixplorer to detect portal hypertension in cirrhosis: an individual patient data meta-analysis

  • Thiele, Maja
  • Hugger, Mie B.
  • Kim, Yongsoo
  • Rautou, Pierre-Emmanuel
  • Elkrief, Laure
  • Jansen, Christian
  • Verlinden, Wim
  • Allegretti, Giulia
  • Israelsen, Mads
  • Stefanescu, Horia
  • Piscaglia, Fabio
  • García Pagán, Juan Carlos
  • Franque, Sven
  • Berzigotti, Annalisa
  • Castera, Laurent
  • Jeong, Woo K.
  • Trebicka, Jonel
  • Krag, Aleksander
Background & Aims: Liver stiffness measured with 2-dimensional shear wave elas- tography by Supersonic Imagine (2DSWE-SSI) is well-established for fibrosis diagnos- tics, but non-conclusive for portal hypertension. Methods: We performed an individual patient data meta-analysis of 2DSWE-SSI to identify clinically significant portal hypertension (CSPH), severe portal hyperten- sion and large varices in cirrhosis patients, using hepatic venous pressure gradient and upper endoscopy as reference. We used meta-analytical integration of diagnos- tic accuracies with optimized rule-out (sensitivity-90%) and rule-in (specificity-90%) cut-offs. Results: Five studies from seven centres shared data on 519 patients. After exclu- sion, we included 328 patients. Eighty-nine (27%) were compensated and 286 (87%) had CSPH. 2DSWE-SSI < 14 kPa ruled out CSPH with a summary AUROC (sROC), sensitivity and specificity of 0.88, 91% and 37%, and correctly classified 85% of pa- tients, with minimal between-study heterogeneity. The false negative rate was 60%, of which decompensated patients accounted for 78%. 2DSWE-SSI ≥ 32 kPa ruled in CSPH with sROC, sensitivity, specificity and correct classifications of 0.83, 47%, 89% and 55%. In a subgroup analysis, the 14 kPa cut-off showed consistent sensitivity and higher specificity for patients with compensated cirrhosis, without ascites, viral 2 aetiology or BMI < 25 kg/m . 2DSWE-SSI ruled out severe portal hypertension and large varices with fewer correctly classified and lower sROC, and with minimal benefit for ruling in. Conclusion: Liver stiffness using 2-dimensional shear wave elastography below 14 kPa may be used to rule out clinically significant portal hypertension in cirrhosis patients, but this would need validation in populations of compensated liver disease. 2DSWE-SSI cannot predict varices needing treatment.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis

  • Queck, Alexander
  • Thomas, Dominique
  • Jansen, Christian
  • Schreiber, Yannick
  • Rüschenbaum, Sabrina
  • Praktiknjo, Michael
  • Schwarzkopf, Katharina Maria
  • Mücke, Marcus Maximilian
  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Meyer, Carsten
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Geisslinger, Gerd
  • Trebicka, Jonel
  • Lange, Christian Markus
BACKGROUND: Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated. METHODS: Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein. RESULTS: While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001). CONCLUSIONS: Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03584204.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Cañete Hidalgo, Nuria
  • Bañares, Rafael
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p <0.001) and mortality (47% vs. 10%; p <0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality in patients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt., CIBERehd is funded by Instituto de Salud Carlos III . Juan Carlos Garcia - Pagan is supported by Ministerio de Educacion y Ciencia ( SAF - 2016 - 75767 - R ). Virginia Hernández - Gea is supported by Instituto de Salud Carlos III ( PI14/00182 ). Gilberto Silva - Junior is funded by CAPES Foundation, Ministry of Education of Brazil , Brasilia, Brazil (process number BEX 5960/13 - 4 ). Edilmar Alvarado is supported by a Rio Hortega Fellowship grant form Instituto de Salud Carlos III . Jonel Trebicka is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), European Union's Horizon 2020 Research and Innovation Programme ( Galaxy , No. 668031 and MICROB-PREDICT , No. 825694 ) and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875 ), and Cellex Foundation (PREDICT). Gu W is supported by the China Scholarships Council (CSC: #201906230332 ). Rafael Bañares is funded by Instituto de Salud Carlos III ( PI18/01901 ). Michael Praktiknjo is funded by the Ernst und Berta Grimmke Stiftung (Lfd.Nr. 5/19). The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Gu, Wenyi
  • Ibáñez Samaniego, Luis
  • Castellote Alonso, José
  • Silva Junior, Gilberto
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & Aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of trans-jugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p<0.001) and mortality (47% vs. 10%; p<0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality inpatients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Statins: Old drugs as new therapy for liver diseases?

  • Pose Méndez, Elisa
  • Trebicka, Jonel
  • Mookerjee, Rajeshwar P.
  • Angeli, Paolo
  • Ginès i Gibert, Pere
In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large populations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins, with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial effects persisted after adjustment for disease severity and other potential confounders. Finally, a few randomised controlled trials have shown that treatment with simvastatin decreases portal pressure (two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects, further randomised controlled trials in large series of patients with hard clinical endpoints should be performed before statins can be recommended for use in clinical practice.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?

  • Schwarzkopf, Katharina Maria
  • Eberle, Larissa
  • Uschner, Frank Erhard
  • Klein, Sabine
  • Schierwagen, Robert
  • Muecke, Marcus M.
  • Schaefer, Liliana
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Hintermann, Edith
  • Christen, Urs
  • Lange, Christian Markus
  • Trebicka, Jonel
  • Welsch, Christoph
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The role of macrophage-inducible C-type lectin in different stages of chronic liver disease

  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Ortiz, Cristina
  • Torres, Sandra
  • Brol, Max J.
  • Tyc, Olaf
  • Gu, Wenyi
  • Grimm, Christian
  • Zeuzem, Stefan
  • Plamper, Andreas
  • Pfeifer, Philipp
  • Zimmer, Sebastian
  • Welsch, Christoph
  • Schaefer, Liliana
  • Rheinwalt, Karl P.
  • Clària i Enrich, Joan
  • Arroyo, Vicente
  • Trebicka, Jonel
  • Klein, Sabine
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.